Placeholder Banner

BIO Comments to FDA on Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products

August 3, 2023

In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.

Download Full Comments Below
BIO Comment Letter - FDA-2023-N-0743
Discover More
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill.